In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Aortic stiffness in the presence of self-limiting and sustained systemic inflammation: comparison of acute myocarditis and chronic inflammatory diseases

Session Poster session 5

Speaker Rocio Hinojar Baydes

Congress : ESC Congress 2014

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance
  • Session type : Poster Session
  • FP Number : P4459

Authors : R Hinojar (London,GB), E Arroyo Ucar (London,GB), N Binti Ngah (London,GB), N Kuo (London,GB), D D Cruz (London,GB), N Gaddum (London,GB), T Schaeffter (London,GB), E Nagel (London,GB), VO Puntmann (London,GB)

Authors:
R. Hinojar1 , E. Arroyo Ucar1 , N. Binti Ngah1 , N. Kuo1 , D. D Cruz1 , N. Gaddum1 , T. Schaeffter1 , E. Nagel1 , V.O. Puntmann1 , 1King's College London, Cardiovascular Division, St. Thomas' Hospital - London - United Kingdom ,

Citation:
European Heart Journal ( 2014 ) 35 ( Abstract Supplement ), 792-793

Purpose: Aortic stiffness, measured by pulse way velocity (PWV), is an independent predictor of cardiovascular (CV) events over and above traditional risk factors. Previous evidence revealed moderately raised PWV in the presence of presence of systemic inflammatory diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Changes in aortic stiffness in response to acute systemic inflammation, such as systemic viral myocarditis, remain unknown.

Methods: Ninety-nine subjects with either clinical diagnosis of acute myocarditis (n=44) or chronic systemic inflammatory disease (RA and SLE, n=55) underwent standardized cardiac magnetic resonance protocol for the assessment of PWV. Thirty-eight apparently healthy subjects served as control group. Central PWV was obtained by an inplane phase contrast gradient echo sequence with high temporal resolution (120 phases/cardiac cycle) and foot-to-foot measurement.

Results: Groups were well matched for age and cardiovascular risk factors, with no differences in blood pressure or heart rate between groups. Compared to controls, both patients' groups had significantly raised central PWV (control vs. acute myocarditis vs. systemic inflammation, PWV (m/sec): 5.1±1.0 vs. 8.4±2.4 vs. 8.5±2.6, p<0.001, with no significant differences between the two groups of patients on post-hoc analysis. We identified significant relationship between PWV and age (controls, r: 0.56; acute myocarditis, r: 0.51; and systemic inflammation, r: 0.3 p<0.0001 for all), whereas no other functional index showed significant association.

Conclusion: We demonstrate for the first time that there is increased aortic stiffness in response to self-limiting inflammatory injury, which is comparable in magnitude to sustained systemic inflammation.

PWV bivariate correlations
PWVrSign (p value)
Age0.4<0.05
Hypertension0.34<0.05
Hypercholesterolemia0.24<0.05
Smoking0.22<0.001
LGE0.36<0.001
PWV was significantly correlated with age, with traditional CV risk factors and with the presence of areas of late gadolinium enhancement (LGE) in the CMR study.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are